HBC Hofseth Biocare

Hofseth Biocare ASA: SUPPLEMENTARY ELECTIONS TO BOARD AND AUDIT COMMITTEE – NOTICE OF EGM

Hofseth Biocare ASA: SUPPLEMENTARY ELECTIONS TO BOARD AND AUDIT COMMITTEE – NOTICE OF EGM

The Board of Directors of Hofseth BioCare ASA (the "Company") has resolved to appoint Christoph Baldegger as new member of the audit committee, and has further resolved to propose that the general meeting of the Company elects a new member to the Board of Directors of the Company.

Following discussions between the Company's election committee and the management, it has been proposed to nominate Kristin Fjellby Grung as new member of the Board of Directors.

The appointment of Christoph Baldegger to the audit committee is effective immediately, while the election of Kristin Fjellby Grung as new member of the Board of Directors is subject to approval by the Company's general meeting.

The Board of Directors therefore call for an extraordinary general meeting to be held on 4 December 2020 at 13.00 hours CET at the premises of the Company at Havnegata 11, 6005 Ålesund, Norway. The notice for the extraordinary general meeting is attached hereto.

For further information, please contact:

Jon Olav Ødegård, CFO of Hofseth BioCare ASA

Mob:

E-mail:

About Hofseth BioCare ASA:

HBC is a Norwegian biotech company that develops high-value ingredients and finished products. Ingredients are further developed into discovery and pre-clinical studies in multiple clinics and university research labs in several countries. Lead clinical and pre-clinical candidates are development towards a Gastro-Intestinal (GI) Protective Medical Food, Medical Food to help treat age-related Sarcopenia, and future phase 1 studies on treatment of Anemia and NEC-IBS with Salmon Protein Hydrolysate fractions.

The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC can preserve the quality of lipids, proteins and calcium from fresh salmon off-cuts. Hofseth BioCare's headquarters are in Ålesund, Norway with branches in Oslo, London, Zürich, Chicago, Mumbai, Palo Alto and Tokyo.

HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC". More information about Hofseth BioCare at hofsethbiocare.com and facebook.com/hofsethbiocare

This information is subject to the disclosure requirements pursuant to Sections 4-3 and 5-12 of the Norwegian Securities Trading Act

Attachment

EN
11/11/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hofseth Biocare

 PRESS RELEASE

Hofseth BioCare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING

Hofseth BioCare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING Reference is made to the stock exchange announcement by Hofseth BioCare ASA ("HBC" or the "Company") on 27 October 2025 regarding (i) the completion of a private placement (the "Private Placement") of new shares in the Company the "Offer Shares"), the completion of which by delivery of Offer Shares in tranche 2 (the "T2 Offer Shares") is subject to, among other things, an extraordinary general meeting (the "EGM") resolving to issue the T2 Offer Shares in the Private Placement and (ii) a potential subsequent repair offering which i...

 PRESS RELEASE

Hofseth BioCare ASA: Mandatory Notification of Trade

Hofseth BioCare ASA: Mandatory Notification of Trade Reference is made to the stock exchange announcement by Hofseth Biocare ASA ("HBC" or the "Company") on 27 October 2025 regarding completion of a private placement (the "Private Placement") of new shares in the Company. In the Private Placement, Hofseth International AS was allocated 28,666,666 new shares at the subscription price of NOK 1.80. Please refer to the attached notification form for further information. This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19. For furth...

 PRESS RELEASE

Ex. Subsequent Offering Today

Ex. Subsequent Offering Today NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange announcement by Hofseth Biocare ASA ("HBC" or the "Company") on 27 October 2025 relating to a contemplated subsequent offering of up to 16,666,666 new shares directed towards certain eligible shareholders...

 PRESS RELEASE

Hofseth BioCare ASA: Key Information Relating to Subsequent Offering

Hofseth BioCare ASA: Key Information Relating to Subsequent Offering NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange announcement by Hofseth BioCare ASA ("HBC" or the "Company") on 27 October 2025 regarding completion of a private placement (the "Private Placement") of new shares i...

 PRESS RELEASE

Hofseth BioCare ASA: Disclosures of Large Shareholdings

Hofseth BioCare ASA: Disclosures of Large Shareholdings Reference is made to the stock exchange announcement by Hofseth BioCare ASA ("HBC" or the "Company") on 27 October 2025 regarding completion of a private placement (the "Private Placement") of new shares in the Company. The following shareholders of the Company have, on 27 October 2025, been allocated new shares in the Private Placement which implies that their holdings have surpassed a notifiable threshold: Guy Urquhart have subscribed for 55,444,444 new shares in the Private Placement. Following this, Guy Urquhart holds 55,444,444...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch